Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

https://www.prnewswire.com/news-releases/moleculin-announces-commencement-of-nih-funded-phase-2-clinical-trial-of-stat3-inhibitor-for-the-treatment-of-glioblastoma-nu-21c06-302145199.html

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin

Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune “memory” in glioblastoma animal models

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.